Congress, government affairs, healthcare, legislation, Long term care pharmacy, LTC, pharmacy benefit manager, prescription drug costs Ron Lanton Congress, government affairs, healthcare, legislation, Long term care pharmacy, LTC, pharmacy benefit manager, prescription drug costs Ron Lanton

Lanton Law Newsletter is Out

We have released our August newsletter.

We have released our August newsletter. This month we discuss our presentations at the National Association of Specialty Pharmacy, the new Executive Order aimed at PBMs, our recent Blogcast with Ken Kaitin, Professor and Director at the Tufts Center for the Study of Drug Development, the new LTC Congressional pharmacy bill and our interview with Pharmacy Times on Rutledge v. PCMA. Click here to view it.

Read More
biologics, Biosimilars, healthcare, life sciences, pharmaceuticals, pharmacy, CMS, FDA, fintech Ron Lanton biologics, Biosimilars, healthcare, life sciences, pharmaceuticals, pharmacy, CMS, FDA, fintech Ron Lanton

New Lanton Law Specialty Drug Blogcast with Ken Kaitin of Tufts University

We are excited to interview Kenneth Kaitin; Professor and Director for the Tufts Center for the Study of Drug Development at Tufts University School of Medicine in Boston, Massachusetts.

We are excited to interview Kenneth Kaitin; Professor and Director for the Tufts Center for the Study of Drug Development at Tufts University School of Medicine in Boston, Massachusetts.

Our conversation touches on a wide variety of specialty drug issues such as oncology, orphan drugs, value based care, innovative payment models and Boston’s pharmaceutical R&D expansion.

Click here for the interview.

Read More